Currently, there are 175.08M common shares owned by the public and among those 141.11M shares have been available to trade.
The company’s stock has a 5-day price change of -10.87% and -1.84% over the past three months. BBIO shares are trading -33.79% year to date (YTD), with the 12-month market performance down to -8.24% lower. It has a 12-month low price of $21.62 and touched a high of $44.32 over the same period. BBIO has an average intraday trading volume of 2.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.77%, 0.99%, and -11.09% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of BridgeBio Pharma Inc (NASDAQ: BBIO) shares accounts for 74.86% of the company’s 175.08M shares outstanding.
It has a market capitalization of $5.03B and a beta (3y monthly) value of 1.09. The earnings-per-share (ttm) stands at -$2.64. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.02% over the week and 5.35% over the month.
Earnings per share for the fiscal year are expected to increase by 38.59%, and -24.28% over the next financial year.
Looking at the support for the BBIO, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on September 04, 2024, with the firm’s price target at $46. Raymond James coverage for the BridgeBio Pharma Inc (BBIO) stock in a research note released on March 21, 2024 offered a Outperform rating with a price target of $45. BMO Capital Markets was of a view on January 31, 2024 that the stock is Market Perform, while Wells Fargo gave the stock Overweight rating on December 08, 2023, issuing a price target of $58. Wells Fargo on their part issued Overweight rating on December 08, 2023.
